CLEVELAND, April 2, 2021-- S4 Medical moves a step closer in developing the most comprehensive solution to protect the esophagus from thermal injury during catheter ablation procedures for atrial fibrillation (AF) with the closing of their Series A financing. Three new shareholders – Jobs Ohio, Angel Physician Fund, and an unnamed strategic investor -- have come on board, along with existing investors, to help accelerate efforts towards commercialization. The Series A funding will be used primarily to conduct the company's Investigational Device Exemption study, which is estimated to begin in July 2021.